<ARTICLE> 5 <LEGEND> THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM ABBOTT LABORATORIES' 1997 FIRST QUARTER FORM 10-Q AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FORM 10-Q FILING. </LEGEND> <MULTIPLIER> 1,000 <PERIOD-TYPE> 3-MOS <FISCAL-YEAR-END> DEC-31-1997 <PERIOD-START> JAN-01-1997 <PERIOD-END> MAR-31-1997 <CASH> 134,093 <SECURITIES> 18,138 <RECEIVABLES> 1,891,897 <ALLOWANCES> 160,700 <INVENTORY> 1,199,715 <CURRENT-ASSETS> 4,627,438 <PP&E> 8,355,593 <DEPRECIATION> 3,932,048 <TOTAL-ASSETS> 11,200,394 <CURRENT-LIABILITIES> 4,377,610 <BONDS> 931,227 <PREFERRED-MANDATORY> 0 <PREFERRED> 0 <COMMON> 741,200 <OTHER-SE> 4,114,968 <TOTAL-LIABILITY-AND-EQUITY> 11,200,394 <SALES> 2,999,814 <TOTAL-REVENUES> 2,999,814 <CGS> 1,327,331 <TOTAL-COSTS> 1,327,331 <OTHER-EXPENSES> 280,074<F1> <LOSS-PROVISION> 9,322 <INTEREST-EXPENSE> 32,754 <INCOME-PRETAX> 758,618 <INCOME-TAX> 223,792 <INCOME-CONTINUING> 534,826 <DISCONTINUED> 0 <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> 534,826 <EPS-PRIMARY> .69 <EPS-DILUTED> .68 <FN> <F1> OTHER EXPENSES CONSIST OF RESEARCH AND DEVELOPMENT EXPENSES </FN>